• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Creative Bio-Peptides Inc.

Creative Bio-Peptides Inc.

  • Home
  • Company
    • Our Company
    • Our People
  • Science
    • Introduction
    • RECEPTIDES
    • Publications
  • Therapy Areas
    • Persistent Post-Surgical Pain
    • Parkinson’s Disease
    • Opioid Use Disorders
  • News
  • Contact
  • LinkedIn

Parkinson’s Disease

Parkinson’s disease (PD) remains a devastating whole brain disorder of debilitating motor and cognitive symptoms. Up to 40% of PD patients have cognitive deficits at disease onset, while approximately 50-80% of patients are at risk to develop dementia. Cognitive symptoms do not respond to dopamine replacement therapies, which may have negative effects. There is a significant unmet need for neuroprotective disease modifying agents that can prevent, slow, or reverse both cognitive and motor decline, as well as avoid the long-term consequences of current treatments. Earlier clinical versions of our current Receptides (RAP peptides) were effective to reverse cognitive deficits in HIV by blocking CCR5, and we believe similar benefits may be shown in PD for cognitive, and potentially motor improvements. By similar mechanisms, benefits in AD and other dementias may be possible.

 

Footer

Creative Bio-Peptides Inc.

Rockville, MD
USA  20854

  • LinkedIn

  • RAP-103 Inhibits Opioid-derived Dependence, Withdrawal and Respiratory Depression  Jul 19, 2022
  • RAP-103 Benefits in Pain Published Jul 14, 2022
  • BioHealth Innovation Press Release Features Creative Bio-Peptides Nov 30, 2021
  • A Conversation with CBO Michael Simon Apr 8, 2021
  • NIH SBIR AWARD FOR SYNAPSE PROTECTING TREATMENTS FOR ALZHEIMER’S DISEASE Sep 28, 2020
  • CREATIVE BIO-PEPTIDES RECEIVES NIH HEAL AWARD FOR OPIOID ABUSE DISORDERS Jan 20, 2020
  • CREATIVE BIO-PEPTIDES and LEIDOS AWARDED US DOD CONTRACT Jan 18, 2020

Read more news

Copyright © 2023 Creative Bio-Peptides Inc.